MX358883B - Aumentar el rendimiento de particulas similares a virus en plantas. - Google Patents

Aumentar el rendimiento de particulas similares a virus en plantas.

Info

Publication number
MX358883B
MX358883B MX2014003776A MX2014003776A MX358883B MX 358883 B MX358883 B MX 358883B MX 2014003776 A MX2014003776 A MX 2014003776A MX 2014003776 A MX2014003776 A MX 2014003776A MX 358883 B MX358883 B MX 358883B
Authority
MX
Mexico
Prior art keywords
plant
nucleic acid
plants
virus
vlp
Prior art date
Application number
MX2014003776A
Other languages
English (en)
Other versions
MX2014003776A (es
Inventor
Andre D´Aoust Marc-
Couture Manon
Vezina Louis-Philippe
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of MX2014003776A publication Critical patent/MX2014003776A/es
Publication of MX358883B publication Critical patent/MX358883B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para producir una partícula similar a virus (VLP). El método comprende introducir un primer ácido nucleico y un segundo ácido nucleico en la planta, o porción de la planta. El primer ácido nucleico comprende una primera región reguladora activa en la planta y enlazada funcionalmente a una secuencia de nucleótidos que codifican para una proteína viral estructural. El segundo el ácido nucleico comprende una segunda región reguladora activa en la planta y enlazada funcionalmente a una secuencia de nucleótidos que codifica para una proteína de canal, por ejemplo de manera enunciativa para una proteína de canal protónico. La planta o porción de la planta se incuban bajo condiciones que permitan la expresión de los ácidos nucleicos, produciendo con esto la VLP.
MX2014003776A 2011-09-30 2012-09-28 Aumentar el rendimiento de particulas similares a virus en plantas. MX358883B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541780P 2011-09-30 2011-09-30
PCT/CA2012/050681 WO2013044390A1 (en) 2011-09-30 2012-09-28 Increasing virus-like particle yield in plants

Publications (2)

Publication Number Publication Date
MX2014003776A MX2014003776A (es) 2014-08-21
MX358883B true MX358883B (es) 2018-08-31

Family

ID=47994080

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003776A MX358883B (es) 2011-09-30 2012-09-28 Aumentar el rendimiento de particulas similares a virus en plantas.
MX2018006627A MX2018006627A (es) 2011-09-30 2014-03-28 Aumentar el rendimiento de particulas similares a virus en plantas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018006627A MX2018006627A (es) 2011-09-30 2014-03-28 Aumentar el rendimiento de particulas similares a virus en plantas.

Country Status (27)

Country Link
US (1) US11155581B2 (es)
EP (2) EP2760882B1 (es)
JP (1) JP6248040B2 (es)
KR (1) KR101974017B1 (es)
CN (2) CN103930435A (es)
AU (1) AU2012315421C1 (es)
BR (1) BR112014007474A2 (es)
CA (1) CA2850407C (es)
DK (1) DK2760882T3 (es)
ES (1) ES2951259T3 (es)
FI (1) FI2760882T3 (es)
HK (1) HK1200179A1 (es)
HR (1) HRP20230695T1 (es)
HU (1) HUE062759T2 (es)
IL (1) IL231587B (es)
IN (1) IN2014CN03077A (es)
MX (2) MX358883B (es)
MY (1) MY184072A (es)
NZ (1) NZ622731A (es)
PL (1) PL2760882T3 (es)
PT (1) PT2760882T (es)
RU (1) RU2682752C2 (es)
SG (2) SG10201708052XA (es)
SI (1) SI2760882T1 (es)
TW (1) TWI700368B (es)
WO (1) WO2013044390A1 (es)
ZA (1) ZA201403059B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2760882T3 (da) 2011-09-30 2023-07-03 Medicago Inc Forøgelse af udbyttet af viruslignende partikler i planter
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
KR102199018B1 (ko) * 2013-03-28 2021-01-07 메디카고 인코포레이티드 식물에서 인플루엔자 바이러스-유사 입자 생산
ES2864081T3 (es) 2014-01-10 2021-10-13 Medicago Inc Elementos potenciadores de CPMV
EP3122883B1 (en) * 2014-03-27 2022-03-02 Medicago Inc. Modified cpmv enhancer elements
MX2020009495A (es) * 2018-03-14 2020-12-07 Medicago Inc Potenciador de la expresion en plantas.
BR112020026537A2 (pt) * 2018-06-27 2021-04-06 Medicago Inc. Mutantes de hemaglutinina do vírus influenza
WO2020181354A1 (en) * 2019-03-14 2020-09-17 Mitsubishi Tanabe Pharma Corporation Endogenous plant expression enhancer
WO2021236908A2 (en) * 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5805417A (en) 1995-10-13 1998-09-08 Hitachi, Ltd. Heat dissipation structure in a portable computer including a heat dissipation block extending from a heat dissipation plate through a first circuit board to a CPU on a second circuit board
WO2000020557A2 (en) 1998-10-07 2000-04-13 Boyce Institute For Plant Research At Cornell University Gemini virus vectors for gene expression in plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
RU2164148C1 (ru) * 2000-08-09 2001-03-20 Петров Рэм Викторович Вакцина против вируса гриппа и способ ее получения
NZ543348A (en) * 2003-05-05 2008-08-29 Thompson Boyce Plant Res Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
US20040268442A1 (en) 2003-05-05 2004-12-30 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
US8535930B2 (en) * 2005-04-29 2013-09-17 University Of Cape Town Expression of proteins in plants
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
CN103865892B (zh) 2005-10-18 2017-04-12 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(vlp)
US20090169576A1 (en) * 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
KR20090034297A (ko) 2006-02-16 2009-04-07 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 인플루엔자에 대한 항바이러스제 및 백신
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP1998814A4 (en) 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
EP2029755A1 (en) 2006-05-22 2009-03-04 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
CA2654178A1 (en) * 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
HUE031698T2 (en) 2007-06-15 2017-07-28 Medicago Inc Modification of glycoprotein production in plants
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
PT2610345E (pt) * 2007-11-27 2016-01-11 Medicago Inc Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
EA034733B1 (ru) 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
CA2730171C (en) 2008-07-08 2016-10-11 Medicago Inc. Soluble recombinant influenza antigens
WO2010006452A1 (en) 2008-07-18 2010-01-21 Medicago Inc. New influenza virus immunizing epitope
US8513397B2 (en) 2008-08-27 2013-08-20 The Arizona Board Of Regents For And On Behalf Of Arizona State University DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
ES2669303T3 (es) 2009-06-24 2018-05-24 Medicago Inc. Partículas pseudovíricas quiméricas de influenza que comprenden hemaglutinina
FR2947875B1 (fr) 2009-07-10 2011-07-08 Raymond A & Cie Dispositif de fixation a elements de fixation multiples dont l'un est flottant
WO2011011390A1 (en) * 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
PT3354657T (pt) 2009-09-22 2022-05-06 Medicago Inc Método de preparação de proteínas derivadas de plantas
US9352031B2 (en) * 2010-02-18 2016-05-31 Technovax, Inc. Universal virus-like particle (VLP) influenza vaccines
CN103328002B (zh) 2010-10-04 2020-01-14 麻省理工学院 血球凝集素多肽以及与其相关的试剂和方法
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
PL220281B1 (pl) 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
US11390878B2 (en) * 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
DK2760882T3 (da) 2011-09-30 2023-07-03 Medicago Inc Forøgelse af udbyttet af viruslignende partikler i planter
US9555094B2 (en) 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
KR102199018B1 (ko) 2013-03-28 2021-01-07 메디카고 인코포레이티드 식물에서 인플루엔자 바이러스-유사 입자 생산

Also Published As

Publication number Publication date
AU2012315421B2 (en) 2017-10-19
MX2014003776A (es) 2014-08-21
TW201329235A (zh) 2013-07-16
AU2012315421A1 (en) 2014-04-10
EP3626733A1 (en) 2020-03-25
MY184072A (en) 2021-03-17
CN103930435A (zh) 2014-07-16
HRP20230695T1 (hr) 2023-12-22
KR20140068260A (ko) 2014-06-05
JP2014530006A (ja) 2014-11-17
CA2850407C (en) 2021-11-23
IN2014CN03077A (es) 2015-07-03
BR112014007474A2 (pt) 2017-04-04
US11155581B2 (en) 2021-10-26
SI2760882T1 (sl) 2023-10-30
EP2760882A4 (en) 2015-06-10
AU2012315421C1 (en) 2019-12-05
DK2760882T3 (da) 2023-07-03
RU2682752C2 (ru) 2019-03-21
IL231587B (en) 2020-06-30
RU2014116371A (ru) 2015-11-10
SG10201708052XA (en) 2017-11-29
CA2850407A1 (en) 2013-04-04
CN116218900A (zh) 2023-06-06
WO2013044390A1 (en) 2013-04-04
NZ622731A (en) 2016-04-29
HUE062759T2 (hu) 2023-12-28
MX2018006627A (es) 2020-11-12
TWI700368B (zh) 2020-08-01
HK1200179A1 (en) 2015-07-31
KR101974017B1 (ko) 2019-04-30
ES2951259T3 (es) 2023-10-19
EP2760882B1 (en) 2023-05-24
PL2760882T3 (pl) 2023-09-11
PT2760882T (pt) 2023-08-07
US20150104480A1 (en) 2015-04-16
IL231587A0 (en) 2014-05-28
JP6248040B2 (ja) 2017-12-13
EP2760882A1 (en) 2014-08-06
EP3626733B1 (en) 2024-01-24
FI2760882T3 (fi) 2023-07-17
ZA201403059B (en) 2019-07-31
SG11201400712VA (en) 2014-04-28

Similar Documents

Publication Publication Date Title
MX2018006627A (es) Aumentar el rendimiento de particulas similares a virus en plantas.
MX2013014712A (es) Produccion de particulas tipo virus de la rabia en plantas.
PH12018501452A1 (en) Rotavirus-like particle production in plants
MY161891A (en) Virus like particle production in plants
PH12015502217B1 (en) Influenza virus-like particle production in plants
IN2015DN01606A (es)
MX2019004568A (es) Produccion mejorada de derivados de acidos grasos.
WO2012171030A3 (en) Method and apparatus for antibody production and purification
IN2012DN00650A (es)
NZ603918A (en) Improved methods for preparing squalene
WO2014095669A3 (de) Verfahren und anlage zur herstellung von biogas aus lignocellulosehaltiger biomasse
MY185050A (en) A pentose sugar fermenting cell
PH12015500459B1 (en) Picornavirus-like particle production in plants
MY183015A (en) Solvent production using monophasic clostridia
WO2011037367A3 (ko) 고효율 유도만능줄기세포 제조방법 및 상기 방법에 의해 제조된 유도만능줄기세포
TH1401001699A (th) การเพิ่มผลผลิตอนุภาคคล้ายไวรัสในพืช
TH171332A (th) การผลิตอนุภาคคล้ายไวรัสโรคพิษสุนัขบ้าในพืช
WO2012173390A3 (ko) 인유두종바이러스 l1 단백질의 생산 수율을 향상시키는 방법

Legal Events

Date Code Title Description
FG Grant or registration